ViroLogik

ViroLogik is a German biopharmaceutical company specializing in the development of innovative host-cell-based antiviral therapies. Unlike traditional antivirals that target rapidly mutating viral proteins, ViroLogik focuses on essential host cell factors required for viral replication, such as the enzyme deoxyhypusine synthase (DHS). This approach aims to provide broad-spectrum efficacy against various viral strains, including HIV-1, Influenza, and SARS-CoV-2, while maintaining a high genetic barrier to resistance. The company's lead candidate, VL-201, is a small molecule inhibitor that has demonstrated potent antiviral activity in various preclinical and early clinical models. Based in Erlangen, ViroLogik leverages deep expertise in molecular virology and host-pathogen interactions to address unmet needs in infectious disease management. The company's technology platform represents a paradigm shift in antiviral drug discovery by targeting the stable cellular environment rather than the volatile viral genome.